Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sunshine Lake Pharma Co's EBIT per Share for the
six
months ended in Dec. 2025 was HK$0.88.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-0.09.
During the past 12 months, the average EBIT per Share Growth Rate of Sunshine Lake Pharma Co was 24.00% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 1.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Sunshine Lake Pharma Co's EBIT per Share or its related term are showing as below:
HKSE:06887'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 1 Med: 1 Max: 1
Current: 1
During the past 4 years, the highest 3-Year average EBIT per Share Growth Rate of Sunshine Lake Pharma Co was 1.00% per year. The lowest was 1.00% per year. And the median was 1.00% per year.
HKSE:06887's 3-Year EBIT Growth Rate is ranked worse than 61.76% of 808
companies
in the Drug Manufacturers industry
Industry Median: 7.75
vs HKSE:06887: 1.00
Sunshine Lake Pharma Co (HKSE:06887) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Sunshine Lake Pharma Co EBIT per Share Related Terms
Sunshine Lake Pharma Co EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-0.09
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sunshine Lake Pharma Co (HKSE:06887) has a EBIT per Share of HK$-0.09 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Sunshine Lake Pharma Co and its competitors. According to the industry distribution chart, Sunshine Lake Pharma Co ranks #499 out of 808 companies in the Drug Manufacturers industry, placing it in the top 61.8%.
Is Sunshine Lake Pharma Co's EBIT per Share too high?
Sunshine Lake Pharma Co's current EBIT per Share is HK$-0.09. Based on the distribution chart, Sunshine Lake Pharma Co ranks #499 out of 808 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Sunshine Lake Pharma Co has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Sunshine Lake Pharma Co's EBIT per Share compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Sunshine Lake Pharma Co ranks #499 out of 808 companies for EBIT per Share. This places Sunshine Lake Pharma Co in the lower half of its industry. The industry median EBIT per Share is 7.75. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.75, based on 808 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Sunshine Lake Pharma Co and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sunshine Lake Pharma Co's current EBIT per Share is HK$-0.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sunshine Lake Pharma Co stock overvalued right now?
Sunshine Lake Pharma Co (HKSE:06887) has a current EBIT per Share of HK$-0.09. The current EBIT per Share is HK$-0.09. Sunshine Lake Pharma Co's overall GF Score™ is 14/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Sunshine Lake Pharma Co (HKSE:06887), the current EBIT per Share is HK$-0.09 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sunshine Lake Pharma Co Ltd is a vertically integrated pharmaceutical company principally engaged in the research and development, manufacturing and sales of pharmaceuticals. It is focused on therapeutic areas of infectious diseases, chronic diseases and oncology. The company's revenue is mainly derived from sales of pharmaceutical products to distributors in the PRC.
14GF Score
Get the complete analysis for HKSE:06887
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:06887 has been successfully added to your 
